ClinicalTrials.gg
CompletedNCT05984771Updated Aug 9, 2023

Efficacy and Safety of the Combination of Ten Elements for 6 Months in Patients With Diabetic Neuropathy : A Pilot Study

An interventional study of Epineuron and Placebo group in Diabetic Neuropathies, Diabetes Mellitus and Dietary Supplement, sponsored by Aristotle University Of Thessaloniki. Completed at 1 site in Greece. Open to female participants. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by Aristotle University Of Thessaloniki · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Jan 2021, registered Jun 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Sex
Female
01

Study summary

To investigate the efficacy of Superoxide Dismutase (SOD, 70 UI), Palmitoylethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet in patients with Diabetic Neuropathy (DN).

Read the detailed description

To investigate the efficacy of Superoxide Dismutase (SOD, 70 UI), Palmitoylethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet in patients with Diabetic Neuropathy (DN).

Patients - methods: In this pilot study, 61 patients with Diabetes Mellitus Type 2 (DMT2, 31 women), with mean duration of DM 17.5 years and mean age 63 years were randomly assigned, either to receive the combination of ten elements (2 tablets/24h) in the active group, (n=30), or the placebo (n=31) for 6 months. We used Michigan Neuropathy Screening Instrument Questionnaire and Examination (MNSIQ and MNSIE), measured vibration perception threshold (VPT) and Cardiovascular Autonomic Reflex Tests (CARTs). Nerve function was assessed by DPN Check [sural nerve conduction velocity (SNCV) and amplitude (SNAP)]. Sudomotor function was assessed with SUDOSCAN that measures electrochemical skin conductance in hands and feet (ESCH and ESCF). Pain (PS) questionnaire was administered, also. All patients received metformin for at least 4 years.

02

Conditions studied

  • Diabetic Neuropathies
  • Diabetes Mellitus
  • Dietary Supplement

Keywords

  • diabetes mellitus
  • neuropathy
  • pain
03

In context

Diabetic Neuropathies

629 studies on the registry are indexed under Diabetic Neuropathies; 92 are open to participants now.

This study's enrollment of 70 is close to the median of 72 across 522 interventional studies indexed under Diabetic Neuropathies.

Browse Diabetic Neuropathies studies →

Lead sponsor

Aristotle University Of Thessaloniki is the lead sponsor of 281 studies on the registry; 57 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • on metformin therapy for at least 4 years
  • diabetes mellitus type 2 with diabetic neuropathy
  • painful neuropathy

Exclusion criteria

Exclusion Criteria:

  • healthy
  • without diabetic neuropathy
  • pregant
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Active comparator
    Active group

    10-element combination tablet (n=30) Superoxide Dismutase (SOD, 70 UI), Palmitoylethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet for 6 months

    Dietary Supplement: Epineuron

  • Placebo comparator
    Placebo

    usual care

    Other: Placebo group

Interventions

  • Dietary supplementEpineuron

    Superoxide Dismutase (SOD, 70 UI), Palmitoylethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet (Epineuron)

  • OtherPlacebo group

    Usual care

06

What researchers measure

Primary outcomes

  1. Nerve conduction study to measure the velocity of the nerve impulse in the sural nerve

    Measurement of nerve conduction velocity with Neurometrix Diabetic Peripheral Neuropathy scan device

    Time frame: 6 months

  2. Measurement of individual Vibration Perception Threshold to study vibration perception in the feet

    Measurement of vibration perception threshold with Biothesiometer

    Time frame: 6 months

  3. Michigan Screening Neuropathy Questionnaire and Examination

    use of michigan screening questionnaire and examination

    Time frame: 6 months

  4. Measurement of electrochemical skin conductance

    measurement with Sudoscan the electrochemical skin conductance in hands and feet

    Time frame: 6 months

Secondary outcomes

  1. Glycated Hemoglobin

    Measurement of Glycated Hemoglobin

    Time frame: 6 months

  2. vitamin B12 levels

    measurement of B12 levels

    Time frame: 6 months

07

Study locations

1 site
  • University General Hospital AHEPA
    Thessaloniki, Thessaloniki 54621, Greece
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05984771
Responsible party
Prof. Triantafyllos Didangelos (Professor of Internal Medicine and Diabetology, Aristotle University Of Thessaloniki) — Principal investigator
First posted
Aug 9, 2023
Start date
Jan 10, 2021
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Last update
Aug 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion